Viridian Therapeutics, Inc. VRDN Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s deferred revenue?
- Viridian Therapeutics, Inc. (VRDN) reported deferred revenue of $274K in Q1 2026.
- How has Viridian Therapeutics, Inc.'s deferred revenue changed year-over-year?
- Viridian Therapeutics, Inc.'s deferred revenue decreased by 4.9% year-over-year, from $288K to $274K.
- What is the long-term trend for Viridian Therapeutics, Inc.'s deferred revenue?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s deferred revenue has grown at a 4.0% compound annual growth rate (CAGR), from $301K to $367K.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.